▶ Manufacturer: Ilhwa Co., Ltd.
▶ Sold by: Ilhwa Co., Ltd.
▶ Insurance code : 640902430
▶ Storage : Airtight container, store at room temperature (1 to 30℃)
Pale orange elliptical film-coated tablet
Risedronate sodium 35mg
1. Adults : Oral administration of 1 tablet weekly
2. Elderly patients: No need to adjust dose as bioavailability and pharmacokinetics of this drug in elderly patients (aged 60 years of more) is similar to younger patients.
3. Pediatrics: Safety and efficacy for children and growing youth not established.
4. Patients with renal impairment: No need to adjust dose for patients with creatinine clearance of 30ml/min or higher. Use prohibited for severe renal impairment patients with creatinine clearance of less than 30ml/min. Food inhibits absorption of this drug; for sufficient absorption, administer as follows.
Administer at least 30 minutes before breakfast, or at any time of the day at least 2 hours before or after taking food or beverage.
To facilitate delivery of this drug to the stomach and reduce possibility of esophageal irritation, administer in the upright position with a sufficient amount of pure water (170 to 230ml). Administration with other beverages including mineral water may inhibit absorption of this drug. This drug should not be chewed or sucked due to possibility of oral and pharyngeal ulcers. Patient must not lie down for at least 30 minutes after administration. If patient is not consuming sufficient calcium and vitamin D from food, supplements must be administered. In patients with elevated risk of vitamin D deficiency (e.g. patients in excess of 70 years of age, patients in nursing homes, patients with chronic illnesses) may require additional administration of vitamin D supplements. Patients with malabsorption syndrome may need higher dose vitamin D supplements, and 25-hydroxyvitamin D concentration measurement should be considered. Recommended daily vitamin D dose is 400IU to 800IU. This drug provides one week’s worth of 800IU vitamin D intake with once weekly administration. If the patient forgets to administer the drug on the administration date, patient must take the drug when he/she remembers. The next administration shall be on the original administration date. 2 tablets must not be taken on the same date.
1. Treatment and prevention of osteoporosis in post-menopausal women
2. Treatment of male osteoporosisPale orange elliptical film-coated tablet
Risedronate sodium 35mg
1. Adults : Oral administration of 1 tablet weekly
2. Elderly patients: No need to adjust dose as bioavailability and pharmacokinetics of this drug in elderly patients (aged 60 years of more) is similar to younger patients.
3. Pediatrics: Safety and efficacy for children and growing youth not established.
4. Patients with renal impairment: No need to adjust dose for patients with creatinine clearance of 30ml/min or higher. Use prohibited for severe renal impairment patients with creatinine clearance of less than 30ml/min. Food inhibits absorption of this drug; for sufficient absorption, administer as follows.
Administer at least 30 minutes before breakfast, or at any time of the day at least 2 hours before or after taking food or beverage.
To facilitate delivery of this drug to the stomach and reduce possibility of esophageal irritation, administer in the upright position with a sufficient amount of pure water (170 to 230ml). Administration with other beverages including mineral water may inhibit absorption of this drug. This drug should not be chewed or sucked due to possibility of oral and pharyngeal ulcers. Patient must not lie down for at least 30 minutes after administration. If patient is not consuming sufficient calcium and vitamin D from food, supplements must be administered. In patients with elevated risk of vitamin D deficiency (e.g. patients in excess of 70 years of age, patients in nursing homes, patients with chronic illnesses) may require additional administration of vitamin D supplements. Patients with malabsorption syndrome may need higher dose vitamin D supplements, and 25-hydroxyvitamin D concentration measurement should be considered. Recommended daily vitamin D dose is 400IU to 800IU. This drug provides one week’s worth of 800IU vitamin D intake with once weekly administration. If the patient forgets to administer the drug on the administration date, patient must take the drug when he/she remembers. The next administration shall be on the original administration date. 2 tablets must not be taken on the same date.
1. Treatment and prevention of osteoporosis in post-menopausal women
2. Treatment of male osteoporosis
